CLOS
ALLO icon

Compagnie Lombard Odier SCmA’s Allogene Therapeutics ALLO Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-536,738
Closed -$18.9M – 629
2021
Q1 		$18.9M Buy
+536,738
New +$18.1M 0.42% 51

Other funds holding ALLO

TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Compagnie Lombard Odier SCmA's ALLO Position: Q2 2021 in Review

Compagnie Lombard Odier SCmA sold out of Allogene Therapeutics (ALLO) in Q2 2021, closing a stake of 536,738 shares — an estimated $18.9M sold.

Compagnie Lombard Odier SCmA first reported a position in ALLO in Q1 2021 and held it in 1 quarter. The position peaked at $18.9M in Q1 2021. 182 funds tracked by Wall St. Rank hold ALLO as of Q2 2021.

  • Compagnie Lombard Odier SCmA reported no remaining Allogene Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 536,738 Allogene Therapeutics shares in Q2 2021, an estimated $18.9M.
  • Compagnie Lombard Odier SCmA first reported a position in Allogene Therapeutics in Q1 2021 and held it in 1 quarter.
  • Compagnie Lombard Odier SCmA's Allogene Therapeutics position peaked at $18.9M in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2021.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q2 2021, filed 15 Jul 2021.